In 2021, Anivive successfully received conditional approval from the FDA for LAVERDIA®-CA1 to treat lymphoma in dogs. The drug has the potential to be a cutting-edge oral treatment option for canine lymphoma, offering a non-invasive approach for veterinary oncology patients. "The completion of our critical study for LAVERDIA®-CA1 marks a major milestone in bringing forward an innovative therapy for canine lymphoma", said Dylan Balsz, CEO of Anivive. "We are excited to analyze the data and move closer to making an oral treatment option available for dogs living with this challenging disease." Anivive is dedicated to developing novel treatments that improve the lives of companion animals facing cancer and other serious diseases.